Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
|
31518438 |
2020 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, enterolacton, S-equol and urolithin A as representatives of metabolites of lignans, isoflavones and ellagitannins, respectively, were examined for their impact on HCT116 colon cancer cell growth, cooperativity with oxaliplatin and p53 dependency in vitro.
|
30418550 |
2019 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutant p53 in colon cancer.
|
30496442 |
2019 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that protopine exerts its antiproliferative activity by stimulating the p53 pathway and may have potential as a chemopreventive agent for human colon cancer.
|
30932278 |
2019 |
Malignant tumor of colon
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, TP53 mutations were more prevalent in colon cancer with KRAS mutations than in rectal cancer (75.0% vs 28.6%, respectively, p = 0.004).
|
31729406 |
2019 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study, two <i>TP53</i> mutations, corresponding to exon 3 (TP53E3) and 10 (TP53E10), were generated in LS174T cells derived from a wild-type TP53 human colon cancer via a lentiviral CRISPR-Cas9 system.
|
30988165 |
2019 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Quinaldic acid induces changes in the expression of p53 tumor suppressor both on protein and gene level in colon cancer LS180 cells.
|
30780127 |
2019 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
To investigate the molecular mechanisms of cordycepin against colon cancer and in driving apoptosis, p53 and Bcl‑2‑like protein 4‑null (Bax‑/‑) colon cancer HCT116 cell lines were used.
|
30535479 |
2019 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Ulcerative colitis (UC) is an important risk factor for the occurrence of colon cancer, and changes in expression of p53 and inflammatory factors are closely related to the pathogenesis of colon cancer.
|
30906432 |
2019 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that a high dose of glyceollins possibly promotes the growth of p53 wild-type colon cancer through activation of the Nrf2-mediated signaling pathway and, in particular, strong induction of HO-1 expression.
|
30924710 |
2019 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
We also found that CDKN1A expression in mutant p53 colon cancer tissue was significant decreased when compared with p53 wild type colon cancer tissue, while Wnt ligand Wnt5a exhibited the highest level in p53 mutant colon cancer tissue.
|
30833076 |
2019 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
As loss of p53 in colon cancer cells contributes to resistance against anticancer drugs, and thus to reoccurrence of colon cancer, targeted delivery of silica NPs could be envisioned to also deplete p53 deficient tumor cells.
|
31426331 |
2019 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here we sought to investigate the role of miR-150-5p-TP53 signaling pathway in proliferation of colon cancer and to determine expression levels of miR-miR-150-5p and TP53 in colon adenocarcinoma and adjacent non-cancerous tissue samples, or in human colon adenocarcinoma cell lines.
|
31043658 |
2019 |
Malignant tumor of colon
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that both PHD3 and PHD3-H196A suppress the expression of the stem cell-associated gene NANOG and inhibited the properties of colon cancer stem cells through p53.
|
31092600 |
2019 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recent study indicated that BP5 significantly stimulates expression of p53 protein in colon cancer HCT116 cells.
|
31123429 |
2019 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The cytotoxicity of RH1 was inhibited in A549 cells treated with the p53-inhibitor pifithrin-α or transfected p53 siRNA and in human colon cancer HCT116 isogenic (p53<sup>-/-</sup>) cells.
|
30879173 |
2019 |
Malignant tumor of colon
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The effects of exosomes on tumor growth were evaluated using human cell lines (TP53-WT colon cancer, HCT116; TP53-mutant colon cancer, HT29; and fibroblasts, CCD-18Co and WI-38) and an immune-deficient nude mouse xenograft model.
|
31148360 |
2019 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusions:</b> These results indicate that G9a-induced and p53-dependent epigenetic programing stimulates the growth of colon cancer, which also suggests that G9a inhibitors that restore p53 activity are promising therapeutic agents for treating colon cancer, especially for CRC expressing wild-type p53.
|
29774081 |
2018 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
Surface-Enhanced Raman Scattering (SERS) is used to differentiate two colon cancer cell line HCT 116, that is, to distinguish a TP53 gene knockout cell line (p53 -/-) from a wild type (p53 +/+).
|
30059864 |
2018 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mechanistically, miR-423-5p induced the expression of caspases 3, 8 and 9, as well as p53 in colon cancer.
|
30116373 |
2018 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The assessment of both CUL4A and mutant TP53 expression will be helpful in predicting colon cancer prognosis.
|
30562757 |
2018 |
Malignant tumor of colon
|
0.500 |
Biomarker
|
disease |
BEFREE |
The method was applied to the assay of p53 in human plasma sample and normal and malignant cell line lysates such as normal cell Line from mouse C3H (L929), colon cancer cell-HCT, prostate cancer cell line PC-3, and human breast adenocarcinoma cell line-MCF7.
|
29113888 |
2018 |
Malignant tumor of colon
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Wild-type p53 expressing HCT116 colon cancer cells were resistant to apoptosis in response to the MDM2 antagonist Nutlin-3a.
|
29394130 |
2018 |
Malignant tumor of colon
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Wee1 inhibition by small interfering RNA was demonstrated to significantly restrain cancer cell proliferation and sensitize the p53 mutant colonic cancer cell lines HT29 and SW480 to the effect of treatment with ionizing radiation.
|
29257266 |
2018 |
Malignant tumor of colon
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that 6-MSITC might be a potential agent for colon cancer chemoprevention although with p53 mutation.© 2018 BioFactors, 2018.
|
29756671 |
2018 |